Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 3/20 | 0.34 |
| ▸ | EEF2K | O00418 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | GLP1R | P43220 | 1/20 | 0.33 |
| ▸ | GIPR | P48546 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | GCG | P01275 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742024 | 1.00 | PPARG (0.41) | PPARGPPARAGCGREEF2KCTSK | |
| SCHEMBL12241674 | 1.00 | PPARG (0.41) | PPARGPPARAGCGREEF2KCTSK | |
| SCHEMBL1742471 | 0.91 | PPARG (0.38) | PPARGPPARACTSKCTSSCTSL | |
| SCHEMBL1742469 | 0.91 | PPARG (0.38) | PPARGPPARACTSKCTSSCTSL | |
| SCHEMBL12241696 | 0.91 | PPARG (0.38) | PPARGPPARACTSKCTSSCTSL | |
| SCHEMBL12241695 | 0.89 | PPARG (0.37) | PPARGPPARACTSKCTSSCTSL | |
| SCHEMBL1743521 | 0.83 | FFAR1 (0.34) | PPARGPPARAGCGREEF2KCNR2 | |
| SCHEMBL12241693 | 0.83 | CTSK (0.37) | PPARGPPARACTSKCTSSCTSL | |
| SCHEMBL1595742 | 0.82 | PPARG (0.44) | PPARGPPARACTSKCTSSCNR2 | |
| SCHEMBL5019017 | 0.82 | PPARG (0.44) | PPARGPPARACTSKCTSSCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387570-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2010083246-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | PPARG 232/4885PPARA 896/4885GCGR 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.